Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.25 EUR
Change Today +0.02 / 0.47%
Volume 21.6K
ALTER On Other Exchanges
Symbol
Exchange
EN Paris
As of 9:13 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

theradiag (ALTER) Snapshot

Open
€4.28
Previous Close
€4.23
Day High
€4.35
Day Low
€4.20
52 Week High
06/22/15 - €5.98
52 Week Low
12/16/14 - €3.33
Market Cap
24.2M
Average Volume 10 Days
39.3K
EPS TTM
--
Shares Outstanding
5.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERADIAG (ALTER)

Related News

No related news articles were found.

theradiag (ALTER) Related Businessweek News

No Related Businessweek News Found

theradiag (ALTER) Details

TheraDiag SA engages in the development, industrialization, and marketing of diagnosis kits in France and internationally. It offers auto-immunity products, such as FIDIS kits that allow detection of multiple analytes from the same sample in a single assay; immunofluorescence tests to screen and identify the auto-antibodies; ELISA tests for performing various tests on the same plate; Chorus systems, compact multi-parametric analyzers; and immunoblot tests, which allow simultaneous detection of antibodies. The company also provides genetic tests comprising AmplideX products line for the diagnosis of the Fragile X syndrome; xTAG Gastrointestinal Pathogens Panel kits for identifying various gastrointestinal pathogens; xTAG Respiratory Viral Panel kits for identification of common respiratory viruses; Signature series kits dedicated to the FIDIS platform; and BCR/ABL1 Quant tests that are in vitro diagnostic products. In addition, it offers CLA Optigen 30, an in vitro test for the diagnosis of allergy conditions; a panel of reagents for identifying the type of infectious diseases, such as bacteriology, virology, and parasitology; and Immunochromatographic rapid tests for the detection of drugs. Further, the company provides SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos to the computer; OCTEIA 25-Hydroxy Vitamin D kit intended to assay 25-Hydroxy vitamin D and other hydroxylated metabolites present in human serum or plasma; and Serum CrossLaps ELISA kits for the immunoenzyme assay of a specific C-terminal sequence for type I collagen in human serum and plasma. Additionally, it offers a range of instruments, including CARIS, e-Robot, FIDIS, and Chorus instruments. The company was founded in 1986 and is based in Marne La Vallee , France.

64.4 Employees
Last Reported Date: 04/21/15
Founded in 1986

theradiag (ALTER) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €298.1K
Compensation as of Fiscal Year 2014.

theradiag (ALTER) Key Developments

Theradiag Signs Collaboration Agreements with UNICANCER and Bordeaux University Hospital to Advance Micro RNA Project in Rectal Cancer

Theradiag announced that it has signed collaboration agreements with two leading cancer research partners, the UNICANCER group and Bordeaux University Hospital, in order to advance the development of its Circulating microRNAs in Advanced Rectal Cancer (miCRA) project. miCRA was launched in 2013 and rewarded in 2014 as part of the Worldwide Innovation Challenge.

TheraDiag SA Presents at Second French Life Science Days Conference, Jun-17-2015

TheraDiag SA Presents at Second French Life Science Days Conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Theradiag and Hospira Sign Partnership Agreement

Theradiag announced it has entered into a partnership agreement with Hospira regarding the supply of LISA-TRACKER CE-marked infliximab monitoring kit. Theradiag will supply and will also ensure installation and training in laboratories and provide information and follow-up with clinicians on behalf of Hospira. LISA TRACKER infliximab kits have been validated for use with Inflectra®.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALTER:FP €4.25 EUR +0.02

ALTER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALTER.
View Industry Companies
 

Industry Analysis

ALTER

Industry Average

Valuation ALTER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERADIAG, please visit www.theradiag.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.